SCA
SCLN

SAC Capital Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

SAC Capital Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-22,664
Closed -$115K – 2107
2013
Q3 		$115K Buy
+22,664
New +$126K ﹤0.01% 1680

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SAC Capital Advisors's SCLN Position: Q4 2013 in Review

SAC Capital Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2013, closing a stake of 22,664 shares — an estimated $115K sold.

SAC Capital Advisors first reported a position in SCLN in Q3 2013 and held it in 1 quarter. The position peaked at $115K in Q3 2013. 100 funds tracked by Wall St. Rank hold SCLN as of Q4 2013.

  • SAC Capital Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • SAC Capital Advisors sold 22,664 Sciclone Pharmaceuticals Inc shares in Q4 2013, an estimated $115K.
  • SAC Capital Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q3 2013 and held it in 1 quarter.
  • SAC Capital Advisors's Sciclone Pharmaceuticals Inc position peaked at $115K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2013.

Based on SAC Capital Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.